Photo from Manni Mohyuddin/X
Jun 5, 2024, 11:41
Manni Mohyuddin: Suggested approach to 1st relapse of myeloma post – ASCO24
Manni Mohyuddin shared on X/Twitter:
“Suggested approach to 1st relapse of myeloma post ASCO24
Its suddenly more complicated-and bispecifics will change this too.
Bela based triplets >> Dara/Bort/Dex, but CD38+Carfil/Dex still great.
Safety of cilta-cel remains in Q, hard to broadly recommend for now.”
Source: Manni Mohyuddin/X
Dr. Manni Mohyuddin is an Assistant Professor at the Huntsman Cancer Institute, University of Utah, specializing in oncology. He is mainly interested in myeloma, supportive care, end-of-life management, and implementing cost-effective, evidence-based treatment strategies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:20
Dec 21, 2024, 13:12
Dec 21, 2024, 13:05
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30